ALKALINE ALPHA GALACTOSIDASE FOR THE TREATMENT OF FABRY DISEASE
A method of treating Fabry is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease.
1 . A method of treating Fabry disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease.
2 . A pharmaceutical composition comprising as an active ingredient alkaline alpha galactosidase and a pharmaceutically acceptable carrier.
3 . A method of treating Fabry disease in a subject treated with acid alpha galactosidase, the method comprising administering to the subject a therapeutically effective amount of alkaline alpha galactosidase following said treatment with acid alpha galactosidase, thereby treating Fabry disease.
4 - 5 . (canceled)
6 . The method of claim 1 , wherein said alkaline alpha galactosidase is a genetically modified human alpha galactosidase.
7 . The method of claim 1 , wherein said alkaline alpha galactosidase is a plant alpha galactosidase.
8 . The method of claim 1 , wherein said alkaline alpha galactosidase is a purified protein.
9 . The method of claim 1 , wherein said alkaline alpha galactosidase is a recombinant protein.
10 . The method of claim 7 , wherein the plant is a member of a plant family selected from the group consisting of Cucurbitaceae, Lamiaceae, Piperaceae, Solanaceae, Leguminosae, Cruciferae and Gramineae family.
11 . The method of claim 1 , wherein said alkaline alpha galactosidase is selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17 and 19.
12 . The pharmaceutical composition of claim 2 , wherein said alkaline alpha galactosidase is a genetically modified human alpha galactosidase.
13 . The method of claim 3 , wherein said alkaline alpha galactosidase is a genetically modified human alpha galactosidase.
14 . The pharmaceutical composition of claim 2 , wherein said alkaline alpha galactosidase is a plant alpha galactosidase.
15 . The method of claim 3 , wherein said alkaline alpha galactosidase is a plant alpha galactosidase.
16 . The pharmaceutical composition of claim 2 , wherein said alkaline alpha galactosidase is a purified protein.
17 . The method of claim 3 , wherein said alkaline alpha galactosidase is a purified protein.
18 . The pharmaceutical composition of claim 2 , wherein said alkaline alpha galactosidase is a recombinant protein.
19 . The method of claim 3 , wherein said alkaline alpha galactosidase is a recombinant protein.
20 . The pharmaceutical composition of claim 14 , wherein the plant is a member of a plant family selected from the group consisting of Cucurbitaceae, Lamiaceae, Piperaceae, Solanaceae, Leguminosae, Cruciferae and Gramineae family.
21 . The method of claim 15 , wherein said the plant is a member of a plant family selected from the group consisting of Cucurbitaceae, Lamiaceae, Piperaceae, Solanaceae, Leguminosae, Cruciferae and Gramineae family.
22 . The pharmaceutical composition of claim 2 , wherein said alkaline alpha galactosidase is selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17 and 19.
23 . The method of claim 3 , wherein said alkaline alpha galactosidase is selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17 and 19.